# Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC

> **NCT06958614** · — · COMPLETED · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 213 (actual)

## Conditions studied

- Stage II-III Non-small Cell Lung Cancer
- Concurrent Chemotherapy
- Conditions Influencing Health Status

## Interventions

- **DRUG:** Primary Prophylactic Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor

## Key facts

- **NCT ID:** NCT06958614
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-02
- **Primary completion:** 2024-11-07
- **Final completion:** 2025-01-30
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06958614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06958614, "Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06958614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*